May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a phase 2 trial. The biotech showed the candidate depletes mast cells in the ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with the chronic lung disease. The FDA has approved brensocatib (Brinsupri; ...

After Y-mAbs Therapeutics won its first FDA approval more than four years ago, the company has faced numerous hurdles on its quest to become an oncology powerhouse. Now, the drugmaker is moving to ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter. Replimune Group Inc. today announced that it has received ...

– The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeks ...

Elevated absolute eosinophil counts and absolute basophil counts (ABC) are associated with reduced overall survival in essential thrombocythemia. In polycythemia vera, higher ABC correlates with ...

Credit: Getty Images The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as many updated charts and tools. The 2025 update also ...

Assessment of weight change and BMI as prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in a Polish female cohort. A phase I/II study evaluating the safety and ...

Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 ...